The advance of Brigimadlin to Phase III trials underscores its potential in addressing rare cancers like dedifferentiated liposarcoma, while its application to TP53-wild-type tumors with MDM2 overexpression points to broader therapeutic horizons (NCT05218499) [122,123]. Here, MDM2 is linked to cancer.